Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.

Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.

Item
http://www.wikidata.org/entity/Q50919466
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategyEpidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatmentA novel insertion mutation on exon 20 of epidermal growth factor receptor, conferring resistance to erlotinib.Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinibLung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?Epidermal growth factor receptor mutations in lung adenocarcinoma.Republished: lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review.Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.EGFR mutations in non-small cell lung cancer: an audit from West China Hospital.Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer.A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC.Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report.Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations.[Predictive role of EGFR mutation status on postoperative prognosis in patients with resected lung adenocarcinomas].
P2860

Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.

Item
http://www.wikidata.org/entity/Q50919466
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.
@en
Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.
@nl
type
label
Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.
@en
Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.
@nl
prefLabel
Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.
@en
Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.
@en
P2093
P304
P31
P356
10.1097/JTO.0B013E3182614A9D
P433
P478
P50
P577
P698